<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00316875</url>
  </required_header>
  <id_info>
    <org_study_id>NU 05B5</org_study_id>
    <secondary_id>P30CA060553</secondary_id>
    <secondary_id>NU-05B5</secondary_id>
    <secondary_id>NU-1838-001</secondary_id>
    <secondary_id>NCI-2011-00325</secondary_id>
    <nct_id>NCT00316875</nct_id>
  </id_info>
  <brief_title>Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of Lapatinib in Combination With Liposomal Doxorubicin in Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Drugs used in chemotherapy, such as doxorubicin hydrochloride&#xD;
      liposome work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Giving lapatinib together with doxorubicin&#xD;
      hydrochloride liposome may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of doxorubicin&#xD;
      hydrochloride liposome when given together with lapatinib in treating patients with&#xD;
      metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate the safety, tolerability, and feasibility of pegylated doxorubicin HCl liposome&#xD;
           (PLD) when administered with lapatinib, particularly in terms of cardiac safety, in&#xD;
           patients with metastatic breast cancer.&#xD;
&#xD;
        -  Determine the optimally tolerated regimen (OTR) of PLD when administered with lapatinib&#xD;
           in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the pharmacokinetic profiles of lapatinib and PLD when given in combination at&#xD;
           the OTR.&#xD;
&#xD;
        -  Describe any preliminary evidence of efficacy of lapatinib and PLD in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study of pegylated doxorubicin HCl liposome&#xD;
      (PLD).&#xD;
&#xD;
      Patients receive oral lapatinib once daily on days 1-28 and PLD IV over at least 30 minutes&#xD;
      on day 1. Treatment repeats every 28 days for up to 8 courses in the absence of disease&#xD;
      progression or unacceptable toxicity. Lapatinib may be continued alone in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of PLD until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 6 patients&#xD;
      experience dose-limiting toxicity.&#xD;
&#xD;
      After completing study treatment, patients are followed for 30 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac safety</measure>
    <time_frame>Throughout treatment and up to 30 days post-treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>After the first cycle of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profiles</measure>
    <time_frame>After treatment completion for 12 patients treated at the maximum tolerated dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>At time of disease progression</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Lapatinib Ditosylate and Doxil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lapatinib ditosylate</intervention_name>
    <description>1500 mg orally daily for as long as patients remain on trial (up to 8 cycles).</description>
    <arm_group_label>Lapatinib Ditosylate and Doxil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxil</intervention_name>
    <description>Administered intravenously (IV) every 4 weeks in a dose-escalating fashion according to a set schedule</description>
    <arm_group_label>Lapatinib Ditosylate and Doxil</arm_group_label>
    <other_name>Doxorubicin HCL Liposome Injection</other_name>
    <other_name>Dox-SL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the breast with evidence of metastatic&#xD;
             disease&#xD;
&#xD;
               -  Epidermal growth factor receptor (EGFR) and/or erbB2 positivity not required&#xD;
&#xD;
          -  Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1&#xD;
             dimension as ≥ 20 mm by conventional techniques OR as ≥ 10 mm by spiral CT scan&#xD;
&#xD;
          -  No known brain metastases or leptomeningeal disease&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Male or female patients&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST/ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  LVEF ≥ 50%&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to swallow and retain oral medication&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to lapatinib&#xD;
&#xD;
          -  No gastrointestinal (GI) tract disease resulting in inability to take oral medication&#xD;
&#xD;
          -  No malabsorption syndrome or requirement for IV alimentation&#xD;
&#xD;
          -  No uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Prior trastuzumab (Herceptin ®) allowed&#xD;
&#xD;
          -  Prior anthracyclines allowed provided total dose of doxorubicin hydrochloride ≤ 240&#xD;
             mg/m² or epirubicin ≤ 600 mg/m²&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery, hormonal therapy (other than replacement&#xD;
             therapy), chemotherapy (6 weeks for nitrosoureas or mitomycin C), or radiotherapy and&#xD;
             recovered&#xD;
&#xD;
          -  No prior surgical procedures affecting absorption&#xD;
&#xD;
          -  No prior EGFR-targeting therapies&#xD;
&#xD;
          -  At least 7 days since prior and no concurrent CYP3A4 inhibitors&#xD;
&#xD;
          -  At least 7 days since prior and no concurrent gastric pH modifiers&#xD;
&#xD;
               -  Antacids allowed within 1 hour before and after lapatinib dosing&#xD;
&#xD;
          -  At least 14 days since prior and no concurrent CYP3A4 inducers, including&#xD;
             dexamethasone or dexamethasone equivalent dose &gt; 1.5 mg/day&#xD;
&#xD;
          -  At least 6 months since prior and no concurrent amiodarone&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent prophylactic growth factor support&#xD;
&#xD;
          -  No concurrent herbal medications&#xD;
&#xD;
          -  No other concurrent investigational agents or anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William J Gradishar, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>April 19, 2006</study_first_submitted>
  <study_first_submitted_qc>April 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2006</study_first_posted>
  <last_update_submitted>November 6, 2013</last_update_submitted>
  <last_update_submitted_qc>November 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>William Gradishar</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

